Tamas D.
- Country
- Hungary
- Department
- #2551:Gyermekgyogyaszati Klinika
Research Overview
- Evaluation of Long-term Safety and Tolerability of Inclisiran in Patients with Heterozygous or Homozygous Familial Hypercholesterolemia Post-ORION-16/13 Studies
- Randomized, Double-Blind, Multicenter Study Evaluating Inclisiran Versus Placebo in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
- Evaluation of Pharmacokinetics, Safety, and Efficacy of Empagliflozin in Pediatric Patients with Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 17 of 74 partner sites.
Specializations
Lipid Disorders
The investigator specializes in treating familial hypercholesterolemia, focusing on both heterozygous and homozygous forms of this genetic condition.
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Homozygous Familial Hypercholesterolemia (HoFH)
Particular emphasis is placed on lipid management in pediatric populations, including children from 6 years of age.
Pediatric Medicine
The investigator focuses on pediatric lipid disorders, with expertise in managing cholesterol conditions in young patients.
- Childhood Lipid Management
- Pediatric Cardiovascular Risk Prevention
Specializes in therapeutic interventions for children aged 6 to 12 years with inherited cholesterol disorders.
Long-term Care
The investigator concentrates on extended therapeutic monitoring and management of inherited lipid disorders.
- Long-term Safety Assessment
- Chronic Disease Management
Focuses on continuous assessment of treatment outcomes in genetic cholesterol disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.